Unlocking the power of molecular glues

Christian Ottmann, Luc Brunsveld, Michelle Arkin, Scott Clarke


, Ivan Burkov


Some of the most wanted therapeutic drug targets are still considered undruggable. The cutting edge research of Ambagon’s scientific founders has identified a way to solve this challenge through the use of “molecular glues” that stabilize native interactions of the 14-3-3 regulatory proteins. Ambagon’s technology has platform potential and is applicable in a variety of indications beyond cancer.

Christian Ottmann, co-founder & CTO: “Inkef recognized the potential of our technology based on strong scientific rationale, not on the hype”.

Unlocking the power of molecular glues | Inkef